# Management of Solid Lesions of the Stomach

Haejin In, MD, MBA, MPH December 15, 2016






No disclosures





# **Stomach Tumors**

	Considerations prior to resection	Surgical considerations
Carcinoma	Diagnostic laparoscopy Neoadj treatment	3-5cm Margins Lymph node dissection D1 or D2
Sarcoma	Determination of sarcoma type Need for resection if small GIST (<2cm) Neoadj tx if large GIST	No violation of pseudocapsule Negative Margins LND if suspicious nodes
Neuroendocrine	Determination of carcinoid type Surgery typically not indicated for type 1 or 2 Type 3 treated like carcinoma	Type 1 & 2 – endoscopic tx - if multiple and recurrent Type 1 – antrectomy Type 2 – excision of gastrinoma Type 3 – treat like carcinoma
Lymphoma	Primary treatment is non- surgical - Eradication of H. pylori - Chemotherapy - Radiation	Minimal role for surgery



Early disease → Surgery

≥T3 or N+ → Neoadjuvant therapy

M disease → Palliative therapy


<u>Trials</u>
Gastric: MAGIC
GEJx: CROSS


- Tests for diagnosis
  - EGD and biopsy
- Tests for staging
  - T & N staging
    - Endoscopic Ultrasound (EUS)\*\*
  - Stage 4 disease
    - CT chest/abdomen/pelvis
    - Laparoscopic Evaluation and Peritoneal cytology\*\*





- T & N staging
  - EUS: Depth of invasion & presence of LN
  - 80% accuracy








(cross-section of stomach wall)

Laparoscopic Evaluation and Peritoneal cytology





Up to 1/3 of patients considered resectable after imaging work up will have disease!






Laparoscopic Evaluation and Peritoneal cytology





Positive Peritoneal cytology is classified as M1

- Laparoscopic Evaluation and Peritoneal cytology
  - 1. Examine peritoneal cavity for gross metastatic disease *without* disturbing organs
  - 2. Peritoneal washings: 3-4 quadrants, 30-50cc saline, gentle shake, suction fluid and send.
  - 3. Examine tumor and biopsy suspicious lesions






- Oncologic resection in gastric cancer
  - 3-5cm gross negative margins
  - Lymph node clearance of draining nodes

# Gastric Adenocarcinoma Oncologic Resection - Margin

- 3-5cm gross negative margins
  - Distal cancers (body, antrum) -> subtotal gastrectomy
  - Proximal cancers (fundus) -> total gastrectomy




# Gastric Adenocarcinoma Oncologic Resection - Lymph Nodes

Extent of lymph node dissection

D1: Perigastric nodes


 D2: Common hepatic, left gastric, celiac, and splenic arteries

 D3: portahepatis and stations adjacent to aorta



# Gastric Adenocarcinoma Oncologic Resection - Lymph Nodes

- Extent of lymph node dissection
  - D1: Perigastric nodes
  - D2: Common hepatic, left gastric, celiac, and splenic arteries
  - D3: portahepatis and stations adjacent to aorta



#### D1 vs D2 dissection

- RCT, Dutch Trial
- Initial report no diff
- 15 year follow-up
  - D2: Gastric cancer related deaths (37% vs 48%), less local and regional recurrence
  - Morbidity with splenectomy

# Gastric Adenocarcinoma Oncologic Resection - Lymph Nodes


- Extent of lymph node dissection
  - D1: Perigastric nodes
    - D2: Common hepatic, left gastric, celiac, and splenic arteries
  - D3: portahepatis and stations adjacent to aorta



#### Resectable tumors---continued

 Gastric resection should include the regional lymphatics-- perigastric lymph nodes (D1) and those along the named vessels of the celiac axis (D2), with a goal of examining at least 15 or greater lymph nodes <sup>6,7,8</sup>

# D1 LN dissection Omentum, R gastroepiploic & R gastric a LNs




 D1 – removal of involved stomach including greater and lesser omentum, and surrounding lymph nodes (R gastric and R gastroepipolic)

#### D2 LN dissection

Proper and common hepatic, splenic and L gastric

a lymph nodes



# Sarcoma Treatment and Oncologic Resection

- Staging work up Abd/pelvis CT, add chest if high risk
- Biopsy by endoscopy, not percutaneous (risk of hemorrhage and intraperitoneal dissemination)
- Surgery is mainstay of treatment

#### Sarcoma resection principles

- Preservation of pseudocapsule, avoidance of tumor spillage
- Margins: negative
- Lymph nodes: no need for prophylactic LND. LND should be done if pathologically enlarged LNs are encountered.



### **GIST**

- Less than 2cm can observe with surveillance if without high risk features
  - High risk features by EUS (NCCN 2.2016)
    - Irregular borders
    - Cystic spaces
    - Ulceration
    - · Echogenic foci
    - Heterogeneity
- Very large GISTs neoadjuvant Gleevec can be considered
- Post-operative pathologic review to determine need for adjuvant Gleevec

# **Stomach Tumors**

	Considerations prior to resection	Surgical considerations
Carcinoma	Diagnostic laparoscopy Neoadj treatment	3-5cm Margins Lymph node dissection D1 or D2
Sarcoma	Determination of sarcoma type Need for resection if small GIST (<2cm) Neoadj tx if large GIST	No violation of pseudocapsule Negative Margins LND if suspicious nodes
Neuroendocrine	Determination of carcinoid type Surgery typically not indicated for type 1 or 2 Type 3 treated like carcinoma	Type 1 & 2 – endoscopic tx - if multiple and recurrent Type 1 – antrectomy Type 2 – excision of gastrinoma Type 3 – treat like carcinoma
Lymphoma	Primary treatment is non- surgical - Eradication of H. pylori - Chemotherapy - Radiation	Minimal role for surgery